Treatment of Adolescent Suicide Attempters (TASA)

June 18, 2020 updated by: New York State Psychiatric Institute
The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Study Type

Interventional

Enrollment

120

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins University
    • New York
      • New York, New York, United States, 10016
        • New York University Child Study Center
      • New York, New York, United States, 10032
        • Columbia University at the New York State Psychiatric Institute
    • North Carolina
      • Durham, North Carolina, United States, 27705
        • Duke University Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • University of Pittsburgh - Western Psychiatric Institute and Clinic
    • Texas
      • Dallas, Texas, United States, 75235
        • University of Texas, Southwestern Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least one suicide attempt or interrupted attempt within the past 45 days
  • Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

New York State Psychiatric Institute

Collaborators

National Institute of Mental Health (NIMH)

Investigators

  • Study Chair: Laurence Greenhill, MD

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2004

Study Completion (ACTUAL)

June 1, 2007

Study Registration Dates

First Submitted

March 24, 2004

First Submitted That Met QC Criteria

March 25, 2004

First Posted (ESTIMATE)

March 26, 2004

Study Record Updates

Last Update Posted (ACTUAL)

June 22, 2020

Last Update Submitted That Met QC Criteria

June 18, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • #4623
  • U10MH066762 (NIH)
  • U10MH066775 (NIH)
  • U10MH066778 (NIH)
  • U10MH066769 (NIH)
  • U10MH066750 (NIH)
  • DDTR B4-ARD

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on escitalopram

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe